Welcome to our dedicated page for Cassava Sciences news (Ticker: SAVA), a resource for investors and traders seeking the latest updates and insights on Cassava Sciences stock.
Cassava Sciences, Inc. (SAVA) is a clinical-stage biotechnology company pioneering Alzheimer's disease research through therapeutic candidate simufilam and diagnostic tool SavaDx. This page aggregates official press releases, regulatory updates, and material event announcements directly from the company and verified sources.
Investors and researchers will find timely updates on Phase 3 clinical trial progress, FDA communications, intellectual property developments, and peer-reviewed study publications. Our curated feed ensures access to SAVA's critical milestones in drug development and diagnostic innovation without promotional commentary.
Key content categories include clinical trial results, partnership announcements with research institutions, financial disclosures related to R&D funding, and scientific presentations at major medical conferences. All materials are organized chronologically to track the company's evolving research narrative.
Bookmark this page for streamlined monitoring of Cassava Sciences' advancements in Alzheimer's therapeutics. For comprehensive analysis, cross-reference updates with SEC filings and scientific publications linked in source materials.
Cassava Sciences (NASDAQ: SAVA) reported Q3 2025 results and a business update on Nov 12, 2025. The company had $106.1M cash at Sept 30, 2025 and estimates year-end 2025 cash of $92–$96M, after incremental Q4 cash use of $10–$14M. Net loss narrowed to $10.8M ($0.22/share) in Q3 2025 from $27.9M a year earlier. R&D expense fell 78% to $4.0M as the Alzheimer’s program was phased out. Cassava plans a proof-of-concept study of simufilam for TSC-related epilepsy in H1 2026, citing positive preclinical results and recent hires including a part-time CMO and a new independent director.
Cassava Sciences (NASDAQ: SAVA) appointed Dawn C. Bir to its Board of Directors effective Oct. 22, 2025.
Ms. Bir is a seasoned biopharmaceutical executive with prior leadership and board roles at Geron (GERN), Soleno Therapeutics (SLNO), Reata (acquired by Biogen), Pharmacyclics (acquired by AbbVie), Genentech, McKesson, and Bristol-Myers Squibb. Management says the appointment strengthens strategic and commercial expertise as Cassava plans to initiate its first clinical study of simufilam in TSC-related epilepsy in the first half of 2026.
Cassava Sciences (NASDAQ: SAVA), a biotechnology company specializing in novel treatments for central nervous system (CNS) disorders, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference.
The company's President and CEO, Rick Barry, will deliver a corporate presentation on Monday, September 8, 2025, at 5 PM ET in New York City. The presentation will be available via webcast, with a replay accessible on Cassava's investor website for approximately 90 days after the event.
Cassava Sciences (NASDAQ: SAVA) reported Q2 2025 financial results and provided significant business updates. The company recorded a net loss of $44.2 million, compared to net income of $6.2 million in Q2 2024, primarily due to a $31.25 million loss contingency for securities litigation settlement.
Key developments include advancing simufilam for TSC-related epilepsy treatment, with promising preclinical results showing a 60% reduction in seizure frequency in mouse models. The company plans to initiate a proof-of-concept study in H1 2026. Cassava strengthened its leadership team with experienced neuroscience professionals, including Dr. Joseph Hulihan as CMO.
Financial position remains solid with $112.4 million in cash as of June 30, 2025, with projected year-end cash between $61-65 million. R&D expenses decreased 66% to $5.1 million due to the completion of the Alzheimer's disease program.
Cassava Sciences (NASDAQ: SAVA) has appointed Dr. Joseph Hulihan as Chief Medical Officer (CMO). Dr. Hulihan, who will dedicate approximately half of his professional time to Cassava, brings over 25 years of industry experience specializing in epilepsy and neurological disorders therapeutics development.
Dr. Hulihan will advise on the clinical development of simufilam, Cassava's investigational treatment for Tuberous Sclerosis Complex (TSC)-related epilepsy. The company plans to initiate a proof-of-concept clinical study in H1 2026. Previously, he served as CMO at Marinus Pharmaceuticals and held senior positions at Johnson & Johnson, contributing to over 25 late-stage neurology clinical trials and authoring more than 70 published papers.
Cassava Sciences (NASDAQ: SAVA) has reported positive preclinical results for simufilam in treating tuberous sclerosis complex (TSC)-related epilepsy. The study, conducted with the TSC Alliance, demonstrated that simufilam showed beneficial effects on seizure activity with a positive dose response in a Tsc1-knockout mouse model.
The research validates previous findings published in Science Translational Medicine and supports simufilam's potential as a first-in-class treatment for TSC-related epilepsy. The study showed statistically significant correlation between simufilam dose and reduced seizure numbers. The company plans to initiate a proof-of-concept clinical study in H1 2026.
Cassava Sciences (NASDAQ: SAVA) presented promising preclinical data for simufilam in treating Tuberous Sclerosis Complex (TSC)-related epilepsy at the TSC International Research Conference. The research demonstrated that simufilam reduced seizure frequency by 60% compared to vehicle in a mouse model of focal onset seizures.
Key findings from the preclinical studies conducted at Yale School of Medicine showed statistically significant seizure reduction (p<0.0001) and improved seizure freedom rates (11/32 simufilam-treated mice vs 3/29 vehicle-treated mice, p=0.0343). The effective dose was 20 mg/kg/day, with no adverse effects observed at doses up to 50 mg/kg/day in rats and 1250 mg/kg/day in mice.
Additionally, the company presented favorable human safety data from two Phase 3 studies involving 1,929 patients with mild-to-moderate Alzheimer's disease. The safety profile showed only mild, non-serious adverse events typically unrelated to simufilam, with no serious adverse events assessed as study-drug related. Cassava plans to initiate human clinical studies for TSC-related epilepsy in H1 2026.
Cassava Sciences (NASDAQ: SAVA) has appointed Dr. Angélique Bordey as Senior Vice President of Neuroscience to lead the company's research and development efforts. Dr. Bordey, who currently serves as Vice Chair of the Department of Neurosurgery at Yale School of Medicine, will maintain her academic position part-time while focusing on evaluating simufilam as a potential treatment for TSC-related epilepsy and other pipeline indications.
Dr. Bordey's research, published in prestigious journals, was fundamental to Cassava's recently granted patent for using simufilam to treat TSC-related epilepsy. The company has secured a license agreement with Yale University for this patent. Her expertise in neuroscience and leadership in the TSC community is expected to advance Cassava's preclinical program and facilitate study collaborations.
Cassava Sciences (NASDAQ: SAVA) announced key leadership changes in its clinical development team. Dr. James W. Kupiec, Chief Medical Officer, will retire effective May 9, 2025, after completing the company's Alzheimer's disease clinical trial program. Dr. Jack Moore has been appointed as Senior Vice President of Clinical Development, effective April 28, 2025.
Dr. Moore will focus on advancing the clinical evaluation of simufilam for new potential indications, including tuberous sclerosis complex (TSC)-related epilepsy. He brings extensive experience in medical affairs and clinical development from leading global pharmaceutical companies, particularly in CNS disorders.
FAQ
What is the current stock price of Cassava Sciences (SAVA)?
What is the market cap of Cassava Sciences (SAVA)?
